Simone Holden, PA
Physician Assistant · Philadelphia, PANPI 1194152264
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.8%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by Pfizer at 49.3% of the total. Among physician assistant clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 508 payments — averaging $33.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$8K
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$896
- Celltrion USA Inc.$674
- Johnson & Johnson$671
- plus $3K from 20 others
What the payments were for
- Consulting fees$3842%
- Speaking & faculty fees$7,42544%
- Travel & lodging$921%
- Food & beverage$8,88853%
- Education$310%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 61 | $8,284 |
| AbbVie | 116 | $1,805 |
| Takeda Pharmaceuticals U.S.A., Inc. | 73 | $1,157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 49 | $896 |
| Celltrion USA Inc. | 12 | $674 |
| Johnson & Johnson(2 entities) | 31 | $671 |
| Ardelyx, Inc. | 36 | $599 |
| Sanofi | 13 | $483 |
| Regeneron Healthcare Solutions, Inc. | 25 | $425 |
| Bristol Myers Squibb | 29 | $341 |
| E.r. Squibb & Sons, L.L.C. | 3 | $340 |
| Lilly USA, LLC | 16 | $297 |
| Gilead | 7 | $224 |
| Madrigal Pharmaceuticals | 7 | $128 |
| Phathom Pharmaceuticals, Inc. | 7 | $102 |
| Ironwood Pharmaceuticals, Inc | 5 | $82 |
| Novo Nordisk | 3 | $76 |
| QOL Medical, LLC | 4 | $69 |
| Intercept Pharmaceuticals, Inc. | 3 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $29 |
| GSK | 1 | $18 |
| Blueprint Medicines Corporation | 1 | $17 |
| Amgen | 1 | $16 |
| Organon | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,820 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 26 | $702,441 |
| Humira(Cf) PenAdalimumab | 34 | $254,176 |
| RinvoqUpadacitinib | 24 | $206,939 |
| CreonLipase/Protease/Amylase | 39 | $91,023 |
| LinzessLinaclotide | 84 | $74,494 |
| XifaxanRifaximin | 13 | $35,337 |
| Mesalamine | 38 | $24,984 |
| TrulancePlecanatide | 11 | $12,341 |
| Dexlansoprazole DrDexlansoprazole | 17 | $6,878 |
| Omeprazole | 343 | $5,173 |
| Pantoprazole Sodium | 318 | $4,880 |
| Mesalamine ErMesalamine | 13 | $4,471 |
| Balsalazide Disodium | 18 | $3,607 |
| Colestipol Hcl | 15 | $3,511 |
| Esomeprazole Magnesium | 37 | $3,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $671 | $702,44126 claims |
| AbbVieRinvoq, Creon, Linzess | $1,805 | $372,457147 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $896 | $47,67824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.
Other physician assistant in Philadelphia
- Melissa FerrariPhiladelphia$223K
- Alvin KingcadePhiladelphia$68K
- Trevor BonneyPhiladelphia$44K
- Ashwin GuptaPhiladelphia$33K
- Christopher EsworthyPhiladelphia$31K
- Carolyn ZawislakPhiladelphia$29K
- Kristen JonesPhiladelphia$22K
- Erin CrownState College$1.2M
- Tricia BootsCranberry Twp$313K
- Jason OberdickWexford$206K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.